Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology

Journal of Nuclear Medicine

Volumn 54, Issue 11, 2013, Pages 1876-1882

  Viola Villegas, Nerissa Therese ^a   Rice, Samuel L ^a   Carlin, Sean ^a   Wu, Xiaohong ^a   Evans, Michael J ^a   Sevak, Kuntal K ^a   Drobjnak, Marija ^a   Ragupathi, Govind ^a   Sawada, Ritsuko ^b   Scholz, Wolfgang W ^b   Livingston, Philip O ^b   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Mabvax   (United States)

Author keywords

CA19.9; Pancreatic adenocarcinoma; PET imaging

Indexed keywords

CA 19-9 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5B1; TRACER; UNCLASSIFIED DRUG; ZIRCONIUM 89; CARBOHYDRATE ANTIGEN 199, HUMAN; RADIOISOTOPE; TUMOR ANTIGEN; TUMOR MARKER; ZIRCONIUM; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD ANALYSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; IMMUNOREACTIVITY; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VALIDATION STUDY; ANIMAL; BLOOD; CELL TRANSFORMATION; DIAGNOSTIC USE; HUMAN; NEOPLASM; PATHOLOGY; PROCEDURES; SCINTISCANNING; TUMOR CELL LINE; CA19.9; METHODOLOGY; PET IMAGING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; TUMOR MARKERS, BIOLOGICAL; ZIRCONIUM;

CA19.9; PANCREATIC ADENOCARCINOMA; PET IMAGING;

EID: 84891674962     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.119867     Document Type: Article

References (33)

1. Ulmert D, O'Brien MF, Bjartell AS, Lilja H. Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol. 2009;6:384-391.
2. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268-278.
3. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-9343.
4. Nossov V, Amneus M, Su F, et al. The early detection of ovarian cancer: from traditional methods to proteomics-can we really do better than serum CA-125? Am J Obstet Gynecol. 2008;199:215-223.
5. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119.
6. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270.
7. Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ. Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med. 2009;47:750-754.
8. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957-971.
9. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983;43:5489-5492.
10. Girgis MD, Kenanova V, Olafsen T, McCabe KE, Wu AM, Tomlinson JS. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res. 2011;170:169-178.
11. Sawada R, Sun SM, Wu X, et al. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res. 2011;17:1024-1032.
12. Ulmert D, Evans MJ, Holland JP, et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012;2:320-327.
13. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293-1300.
14. Holland JP, Caldas-Lopes E, Divilov V, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS ONE. 2010;5:e8859.
15. Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with 89Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013;40:3-14.
16. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729-739.
17. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
18. Beattie BJ, Forster GJ, Govantes R, et al. Multimodality registration without a dedicated multimodality scanner. Mol Imaging. 2007;6:108-120.
19. Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS ONE. 2010;5:e10857.
20. Vosjan MJ, Perk LR, Visser GW, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-743.
21. Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. CA19-9 as a potential target for radiolabeled antibody-based positron emission tomography of pancreas cancer. Int J Mol Imaging. 2011;2011:834515.
22. Verel I, Visser GW, Boerman OC, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2003;18:655-661.
23. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994;35:899-908.
24. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer. 1994;73:787-793.
25. Pryma DA, O'Donoghue JA, Humm JL, et al. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J Nucl Med. 2011;52:535-540.
26. Wu AM, Yazaki PJ, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA. 2000;97:8495-8500.
27. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 1993;11:738-750.
28. Hocke M, Dietrich CF. Vascularisation pattern of chronic pancreatitis compared with pancreatic carcinoma: results from contrast-enhanced endoscopic ultrasound. Int J Inflam. 2012;2012:420787.
29. Kauhanen SP, Komar G, Seppanen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250: 957-963.
30. Keogan MT, Tyler D, Clark L, et al. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR. 1998;171:1565-1570.
31. Murakami K. FDG-PET for hepatobiliary and pancreatic cancer: advances and current limitations. World J Clin Oncol. 2011;2:229-236.
32. Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET): usefulness and limitations in "clinical reality." Ann Nucl Med. 2003;17:261-279.
33. Fröhlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med. 1999;40: 250-255.